Background Somatostatin (SST), a primary inhibitor of gastrin-stimulated gastric acid secretion, has potent antitumor and anti-secretory activity in several human cancers. Aims This study was performed to investigate the SST gene expression levels and possible epigenetic mechanisms that regulate expression of SST in gastric adenocarcinomas. Methods Quantitative real-time (RT)-PCR and quantitative bisulfite pyrosequencing were used to study primary gastric cancer tissue samples and cell lines. Results Quantitative RT-PCR analysis revealed downregulation of the SST transcript in 93% of gastric carcinoma samples (30/32), compared with 21 normal samples (P \ 0.001). Because of the presence of a large CpG island in the SST promoter, we next examined its promoter DNA methylation levels by use of quantitative bisulfite pyrosequencing. The results revealed a significant increase in SST promoter DNA methylation in tumor samples compared with normal samples (P \ 0.05). Promoter DNA hypermethylation and silencing of SST was also detected in seven gastric cancer cell lines that we tested. To confirm the role of promoter DNA methylation as an epigenetic mechanism regulating SST expression, AGS gastric cancer cells were treated with 5-Aza-dc. This treatment led to reduction of promoter DNA methylation levels of SST accompanied by restoration of its mRNA expression. Conclusions Our results indicate that promoter DNA methylation levels play a critical role in regulating SST expression in gastric cancer. This finding provides a foundation for further studies on the role of SST in gastric carcinogenesis and its potential as a biomarker for gastric cancers.
Introduction
Gastric adenocarcinoma remains the fourth most common cancer and the second leading cause of cancer death worldwide [1] . The two main tumor sites of gastric cancer are the proximal and distal stomach. Despite a decline in distal (noncardia) gastric cancers, proximal (cardia) gastric cancers have been increasing in incidence in Western countries [1, 2] . The main risk factors for distal gastric cancer include Helicobacter pylori infection and dietary factors, including nitrate intake, excessive salt, and a deficiency in fresh fruit and vegetables, whereas gastroesophageal reflux disease and obesity are important factors in the development of proximal gastric cancer [1] . Gastric cancer remains a disease of poor prognosis and high mortality [3] [4] [5] .
Epigenetically mediated transcriptional silencing events such as increases in DNA methylation regulate important cell functions in all stages of tumor formation and progression [6, 7] . DNA methylation levels can be useful in assessing cancer risk, early detection, prognosis, and prediction of response to cancer therapy [7, 8] . Somatostatin (SST), a peptide hormone, is secreted by the gastrointestinal tract, pancreas, and parts of the central nervous system [9] . Its main functions are to regulate endocrine and exocrine secretion, modulate motor activity, and inhibit gastrin-stimulated gastric acid secretion in the gastrointestinal tract [9] . Several in vitro and in vivo studies have suggested that SST functions as a tumor suppressor gene in human cancers [9] . SST is known to suppress tumor growth through distinct mechanisms that involve inhibition of growth factors and hormones, reduction in vascularization, and regulation of the immune system [10] [11] [12] . Stable analogs of SST are widely used to treat neuroendocrine tumors because they are effective in reducing hormone secretion [10, 11] . In the gastrointestinal tract, SST is a paracrine transmitter; it is normally released from D cells and acts on adjacent or nearby cells to exert its inhibitor effects [10, 11] . In some tumors, however, SST operates through an autocrine mechanism to suppress tumor growth. In this manner, SST is both released from and acts on the tumor itself, primarily through SST receptors type 2 [10, 11] .
In this study, we have investigated the expression of SST in gastric cancer and utilized quantitative bisulfite pyrosequencing for analysis of methylation of its promoter DNA.
Materials and Methods

Tissues Samples
All tissue samples were obtained from the pathology archives at Vanderbilt University (Nashville, TN, USA), and from the National Cancer Institute Cooperative Human Tissue Network (CHTN). All personal identifiers were removed before samples were received. The use of specimens from the archival tissue repository was approved by the Institutional Review Board. All tissue samples included in this study were coded and collected from tissues that remained after completion of diagnosis, and that were otherwise discarded. All tumors and normal gastric mucosal epithelial tissues were histologically verified. The gastric adenocarcinomas were distal (antrum and body) and ranged from well differentiated (WD) to poorly differentiated (PD), stages I to IV, with a mix of intestinal and diffuse-type tumors.
Quantitative Real-Time Reverse Transcription PCR (qRT-PCR) Analysis of SST Total RNA was isolated using the RNeasy mini kit (Qiagen, Valencia, CA, USA), and single-stranded cDNA was subsequently synthesized using the Advantage RT-for-PCR Kit (Clontech, Palo Alto, CA, USA). Expression of SST was evaluated for a set of 53 frozen primary human samples that included 21 normal mucosa of the stomach and 32 samples of gastric carcinoma. Fourteen samples had matching tumor and adjacent normal samples from the same patient. The SST oligos (forward 5 0 -AGAAGTCCCT GGCTGCTG-3 0 , and reverse 5 0 -GTTCCAGGGCATCAT TCTCC-3 0 ) were designed using the online software, Primer 3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_ www.cgi). The qRT-PCR was performed using an iCycler (Bio-Rad, Hercules, CA, USA), with the threshold cycle number determined by use of iCycler software version 3.0. Reactions were performed in triplicate and the threshold numbers were averaged. Results for the SST gene were normalized to HPRT (forward 5 0 -TTGGAAAGGGTGTT TATTCCTCA-3 0 , and reverse 5 0 -TCCAGCAGGTCAGC AAAGAA-3 0 ), which had minimal variation in all normal and tumor samples tested, and is therefore considered to be a reliable and stable reference gene for RT-PCR. Expression was calculated by use of the formula 2 ðRtÀEtÞ =2 RnÀEn ð Þ [13] where Rt is the threshold cycle number for the reference gene (HPRT) observed in the tumor, Et is the threshold cycle number for the experimental gene (SST) observed in the tumor, Rn is the threshold cycle number for the reference gene observed in normal samples, and En is the threshold cycle number for the reference gene observed in normal samples. Rn and En values were calculated as an average for the 21 normal samples. For all the primary gastric carcinoma samples, the gene was considered to be down-regulated if mRNA expression was B0.5 that in normal samples.
DNA Bisulfite Treatment and Pyrosequencing Analysis
DNA was purified using a DNeasy tissue kit (Qiagen). Bisulfite modification of DNA from cell lines and tissues was performed by use of an EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA), in accordance with the manufacturer's recommended procedure. The SST promoter CpG Island (from -83 to ?678 bp from the transcription start site) was identified using a CpG island online search tool (http://www.uscnorris.com/cpgislands2. cpg.aspx). The criterion used for the definition of CpG islands was a DNA fragment C500 bp with G ? C equal to or greater than 55% with an observed CpG/expected CpG of 0.65. A 40-ng aliquot of modified DNA was subjected to PCR amplification of the specific promoter region containing the CpG island. The primers were designed using PSQ assay design software (Biotage, Uppsala, Sweden), where one of the primers was biotin-labeled. The forward primer sequence is AGGGAGAAGGTTGAGAGTAT ATAA, the reverse biotin labeled primer sequence is Bio-AAAAACTAACCAAATCTAAAATCC and the sequence primer is GAAGGTTGAGAGTATATAAG. The Platinum PCR SuperMix High Fidelity enzyme mix (Invitrogen, Carlsbad, CA, USA) was used in the PCR reactions. The PCR products were checked by gel electrophoresis to confirm the size of the product and rule out the possibility of formation of primer dimers. The specific PCR products were then subjected to quantitative pyrosequencing analysis using a Biotage PyroMark MD system in accordance with the manufacturer's recommended procedure. The results were analyzed by use of Pyro Q-CpG 1.0.9 software (Biotage). Percentage methylation in normal samples was compared with that in tumor samples for identification of promoter DNA hypermethylation of SST in tumor samples. Statistical analysis was performed to detect significant changes in the frequencies of DNA methylation of CpG sites between tumor and normal samples.
5-Aza-2 0 -Deoxycytidine (5-Aza) and Trichostatin-A (TSA) Treatment
For validation of the role of promoter DNA hypermethylation in transcriptional regulation of SST in vitro, AGS gastric cancer cell line was used. AGS cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and antibiotics (Invitrogen). Cells were seeded at low density for 24 h, and then treated with 5 lM 5-Aza (Sigma-Aldrich, St Louis, MO, USA) for 72 h or 300 nM Trichostatin A (TSA; Wako, Osaka, Japan) for 24 h. Total RNA and DNA were isolated and purified by use of RNeasy and DNeasy tissue kits (Qiagen), as described above. DNA methylation levels of the CpG nucleotides of the SST promoter were determined by pyrosequencing before and after treatment. The SST mRNA expression levels were determined by qRT-PCR, as described above.
Statistical Analysis
Statistical significance for two groups was determined by use of Student's t-test using GraphPad Prism version 4 software (GraphPad Prism Software, La Jolla, CA, USA). Student's t-test was used to compare the differences between DNA methylation level in normal and gastric carcinoma, differences between mRNA expression in normal and gastric carcinoma, and differences between mRNA expression in unmethylated and methylated gastric adenocarcinoma. The correlation between the DNA methylation level and mRNA expression was determined by Spearman correlation. All P values were based on two-sided tests, and differences were considered statistically significant when the P value was B0.05.
Results
Down-Regulation of SST mRNA Expression in Gastric Carcinoma
qRT-PCR analysis revealed frequent down-regulation of SST mRNA expression in primary gastric carcinoma samples (30/32, 93.8%) compared with 21 normal gastric mucosa samples (P \ 0.001) (Fig. 1a) . Analysis of 14 paired tumor and normal samples further revealed significant (P \ 0.01) down-regulation of SST mRNA expression in tumors compared with their corresponding normal samples (Fig. 1b) .
Promoter DNA Hypermethylation of the SST Gene Correlates with Silencing of mRNA Expression Quantitative analysis of SST promoter DNA methylation using state-of-the-art pyrosequencing technology indicated a significant increase in promoter DNA methylation levels in tumor samples, compared with normal samples (P \ 0.05). Representative results of percentage methylation of the SST gene promoter in gastric carcinoma compared with normal tissue are shown in Fig. 2a . Analysis of DNA methylation in 12 tumor samples revealed a significant increase in the level of DNA methylation compared with adjacent histologically normal samples from the same patients (P \ 0.01). A representative summary is illustrated in Fig. 2b . We further analyzed promoter DNA methylation against mRNA expression levels in 13 samples in which both DNA and RNA were available. Using the Spearman correlation for analysis we found a significant inverse correlation between promoter DNA methylation and mRNA expression for SST (coefficient r = -0.56, P = 0.02) (Fig. 3) . These results suggest that hypermethylation of the SST promoter region is one of the factors involved in suppression of its mRNA expression in gastric carcinomas. To confirm the role of DNA methylation in silencing SST expression, we measured promoter DNA hypermethylation of the SST gene in seven gastric cancer cell lines (AGS, MKN28, MKN45, MKN75, KATOIII, SNU1, and SNU16); all originating from distal gastric locations (antrum or body). More than 50% promoter DNA methylation was observed for all gastric cancer cell lines (Fig. 4a) . Of note, complete loss of SST expression was observed for these seven gastric cancer cell lines. We next used AGS gastric cancer cells as an in vitro model to determine whether interference with the activity of DNA methyltransferases led to re-activation of SST expression. The AGS cells had no detectable level of SST mRNA, and 95% promoter DNA methylation was observed. The 5-Aza treatment led to reduction of DNA methylation from 95 to 76% and reexpression of SST. The combination of 5-Aza and TSA treatment significantly reduced DNA methylation from 95 to 43% and demonstrated a synergistic potent increase in (Fig. 4b) .
Discussion
In this study we have shown that SST mRNA expression is frequently down-regulated in primary gastric cancer samples. By using state-of-the-art pyrosequencing technology for quantitative analysis of promoter DNA methylation of SST we detected increased DNA methylation levels in gastric adenocarcinomas compared with normal gastric mucosa samples. Concordant with the primary tissue samples, the seven gastric cancer cell lines that we tested lacked expression of SST and had high levels of DNA methylation. These results suggested that epigenetic mechanisms could be the leading cause of silencing of SST expression in gastric cancer. DNA hypermethylation and loss of expression of SST has been shown in colon and esophageal cancer [9, 10] . Taken together, silencing of SST could be a critical step in gastrointestinal tract carcinogenesis, irrespective of the anatomical tumor site.
Using AGS gastric cancer cells as an in vitro model for validation of the impact of DNA methylation on SST expression, we showed that treatment with 5-Aza alone led to re-expression of low levels of SST. Combined treatment with 5-Aza and TSA had a synergistic effect on restoration of SST expression. Therefore, both DNA methyl transferase inhibitors and histone deacetylase inhibitors were required for maximum restoration of SST expression, consistent with the interpretation that silencing of SST in gastric cancer is mediated by epigenetic mechanisms that include DNA hypermethylation and histone de-acetylation. Similar synergism after a combination of 5-Aza and TSA was reported in the reactivation of epigenetically silenced tumor suppressor genes [14] . Interestingly, we observed that TSA administration after 5-Aza treatment enhanced the DNA demethylation of SST. These results are concordant with recent studies that suggested that TSA can have a demethylation effect in a gene-specific manner [15, 16] . This effect could be mediated by down-regulation of DNA methyltransferase 3b (DNMT3b) [17] or DNMT1 [18] . However, the detailed mechanism by which TSA increases the demethylation effect of 5-Aza remains unclear and requires further investigation.
Aberrant DNA hypermethylation of gene promoter regions is an important epigenetic mechanism that regulates gene expression leading to down-regulation and silencing of several tumor suppressor genes [19] [20] [21] [22] [23] [24] . Several in vitro and in vivo studies have suggested that SST functions as a tumor suppressor gene in human cancers [9] that can inhibit tumor growth through mechanisms that involve inhibition of growth factors and hormones [11, 12] and reduction in vascularization [11, 12] . Silencing of SST in gastric cancer suggests that one or more of the aforementioned mechanisms could be mediated by loss of SST during gastric carcinogenesis. However, additional studies are needed to document the biological outcome of loss of SST in gastric carcinogenesis.
In summary, this study demonstrates frequent epigenetic regulation of SST expression in gastric cancer. This finding provides a foundation for further studies on the role of SST in gastric carcinogenesis and its potential as a biomarker for early diagnosis, therapy, and prognosis of gastric cancers.
